Update shared on27 Aug 2025
Fair value Increased 4.20%Beam Therapeutics’ consensus price target has increased to $45.92, reflecting notable improvements in net profit margin and a lower future P/E, signaling enhanced profitability and a more attractive valuation.
What's in the News
- BEAM-101 for sickle cell disease received FDA RMAT and orphan drug designations; updated Phase 1/2 BEACON data show strong, durable increases in fetal hemoglobin, with sustained safety and efficacy for 17 treated patients.
- BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency demonstrated dose-dependent correction of the genetic mutation, restoration of functional protein, excellent tolerability, and durability across 17 patients; registrational dose selection underway, with expanded dosing cohorts and additional data expected in early 2026.
- Beam Therapeutics was removed from several Russell value benchmarks but added to corresponding Russell growth benchmarks, reflecting a reclassification from value to growth indices.
Valuation Changes
Summary of Valuation Changes for Beam Therapeutics
- The Consensus Analyst Price Target has risen slightly from $44.07 to $45.92.
- The Net Profit Margin for Beam Therapeutics has significantly risen from 14.17% to 18.33%.
- The Future P/E for Beam Therapeutics has significantly fallen from 504.91x to 411.03x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.